Published on
Mar 3, 2026
<![CDATA[Patent Term Extension: Challenges with Defining and Claiming Approved Biologics]]>
For biologic drug developers, the period of market exclusivity following FDA approval can be worth billions. Patent term extension (PTE) under 35 U.S.C. § 156 compensates inventors for time lost during U.S. Food and Drug Administration (FDA) regulatory …
Source:
Pharmaceutical Executive
-
Pending
